However, based on the gradual promotion and application of anti-PD1 therapy in various tumor treatments, with the gradual optimization of relevant drug production technology and the support of the government, we believe that it will become an affordable and cost-effective drug for more people in the near future. Here, RPL17 is linked to neoplasm.